High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1897-4287
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients ; volume:7 ; number:1 ; day:25 ; month:2 ; year:2009 ; pages:1-7 ; date:12.2009
Hereditary cancer in clinical practice ; 7, Heft 1 (25.2.2009), 1-7, 12.2009
- Urheber
-
Suspitsin, Evgeny N.
- Beteiligte Personen und Organisationen
-
Sherina, Nathalia Yu
Ponomariova, Daria N.
Sokolenko, Anna P.
Iyevleva, Aglaya G.
Gorodnova, Tatyana V.
Zaitseva, Olga A.
Yatsuk, Olga S.
Togo, Alexandr V.
Tkachenko, Nathalia N.
Shiyanov, Grigory A.
Lobeiko, Oksana S.
Krylova, Nadezhda Yu
Matsko, Dmitry E.
Maximov, Sergey Ya
Urmancheyeva, Adel F.
Porhanova, Nathalia V.
Imyanitov, Evgeny N.
SpringerLink (Online service)
- DOI
-
10.1186/1897-4287-7-5
- URN
-
urn:nbn:de:1111-201607101743
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Suspitsin, Evgeny N.
- Sherina, Nathalia Yu
- Ponomariova, Daria N.
- Sokolenko, Anna P.
- Iyevleva, Aglaya G.
- Gorodnova, Tatyana V.
- Zaitseva, Olga A.
- Yatsuk, Olga S.
- Togo, Alexandr V.
- Tkachenko, Nathalia N.
- Shiyanov, Grigory A.
- Lobeiko, Oksana S.
- Krylova, Nadezhda Yu
- Matsko, Dmitry E.
- Maximov, Sergey Ya
- Urmancheyeva, Adel F.
- Porhanova, Nathalia V.
- Imyanitov, Evgeny N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population
Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
A case–control study of BRCA1 founder mutations 185delAG and 5382insC in a cohort of Egyptian ovarian cancer patients using pyrosequencing technique